Best of ASCO - 2014 Annual Meeting

 

Welcome

Pediatric Solid Tumors

Pediatric Oncology

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase I NANT study of lenalidomide with ch14.18 and isotretinoin (RA) in patients with refractory/recurrent neuroblastoma (RR-NB).

Araz Marachelian

10522

A prospective study of pediatric renal cell carcinoma: A report from the Children’s Oncology Group study AREN0321.

James I. Geller

10516

ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors.

Suman Malempati

10556

Aqueous humor genomics predicts eye salvage in retinoblastoma.

Liya Xu

10519

Cediranib phase II study in children with metastatic alveolar soft part sarcoma (ASPS).

John Glod

10540

Clinical features and long-term sequelae among children with neuroblastoma and opsoclonus-myoclonus syndrome at diagnosis: Experience of the Instituto Nacional de Pediatria, Mexico City, Mexico.

Araceli Castellanos-Toledo

e22509

Dabrafenib in pediatric patients with BRAF V600–positive high-grade glioma (HGG).

Darren R Hargrave

10505

Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed refractory low-grade glioma.

Mark W. Kieran

10506

Final results of the phase II, single arm trial of irinotecan and cisplatin in children with high-risk glial tumors.

Ofelia Cruz

10549

First-in-child trial of celyvir (autologous mesenchymal stem cells carrying the oncolytic virus ICOVIR-5) in patients with relapsed and refractory pediatric solid tumors.

Manuel Ramirez

10543

Frequency of cancer therapy-related late effects among long-term Wilms' tumor survivors in a 20-year period at the Instituto Nacional de Pediatria, Mexico city, Mexico.

Araceli Castellanos-Toledo

e22508

GD2 as a circulating tumor biomarker (CTB) for neuroblastoma (NBL).

Frank M. Balis

10538

Gene expression analysis for improved subtyping of high-risk neuroblastoma.

Jacob Pfeil

10559

Heterogeneity of pediatric hepatocellular carcinoma.

Amber M D'Souza

e22505

Identification and validation of a 24-gene expression signature for subtype classification of medulloblastoma.

Qinghua Xu

10553

Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls.

Ruth Lydia Ladenstein

10539

In vitro and xenograft anti-tumor activity, target modulation and drug synergy studies of PV-10 against refractory pediatric solid tumors.

Lucy Swift

10557

KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1–positive advanced, relapsed or refractory solid tumor or lymphoma.

Birgit Geoerger

10525

Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).

Gianni Bisogno

LBA2

NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma.

Araz Marachelian

10558

Nasopharengeal carcinoma in children: Demographic, clinical, therapeutic characteristics and long term outcome of 97 patients.

Rejin Kebudi

10547

Outcomes for young children with molecularly defined ependymoma treated on the multi-institutional SJYC07 clinical trial.

Santhosh Upadhyaya

10548

Parallel genomic and immune profiling of relapsed and metastatic osteosarcoma to reveal bases of low immunogenicity.

J Andrew Livingston

10520

Pediatric preclinical testing consortium evaluation of the EZH2 inhibitor tazemetostat in orthotopic PDX models of pediatric brain tumors.

Xiao-Nan Li

10551

Phase 1 multicenter trial to assess the maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.

Kieuhoa Tran Vo

TPS10576

Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.

Ami Vijay Desai

10536

Phase 1 study of olaratumab as monotherapy and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors: Part A results.

Steven G. DuBois

10541

Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN).

Birgit Geoerger

10537

Phase 1/2 intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.

Cornelis Martinus van Tilburg

10535

Phase I multicenter trial of CUDC-907 in children and young adults with relapsed/refractory solid tumors, CNS tumors, and lymphomas.

David Stephen Shulman

10542

Phase II trial of irinotecan/temozolomide/dinutuximab/granulocyte macrophage colony stimulating factor (I/T/DIN/GMCSF) in children with relapsed/refractory neuroblastoma (NBL): A report from the Children's Oncology Group (COG).

Rajen Mody

10508

Plasma cell-free DNA for noninvasive molecular profiling in high-risk stage 4 neuroblastoma.

Prachi Kothari

10554

Preclinical effect of selinexor (KPT-330), a selective inhibitor of nuclear export, in pediatric rhabdoid tumors.

Lianna Jean Marks

10552

Predictors of differential response to induction chemotherapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).

Navin R. Pinto

10532

Prospective study of ophthalmic artery chemosurgery (OAC) as alternative to enucleation in retinoblastoma.

Isabelle Aerts

10555

Rate of MYC-N gene amplification among children of Middle Eastern descent with neuroblastoma.

Teresa Santiago

e22507

Rhabdomyosarcoma in the first year of life: outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS).

Monika Sparber-Sauer

10534

Risk group accurately predicts outcome in primary extremity non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients <30 years of age: Findings from Children’s Oncology Group study ARST0332.

Sara Regina Kreimer

10546

Risk prediction based on post induction bone marrow response and genomic profile: A new way to stratify stage M neuroblastoma patients?

Stefan Fiedler

10550

ROR1-specific CAR for neuroblastoma using sleeping beauty-modified t cells.

Fiorela Natali Hernandez Tejada

10523

SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

Andrea M. Gross

10503

Survival and delayed effects of risk-stratified hepatoblastoma patients treated in the JPLT-2 trial.

Eiso Hiyama

10524

Targeted resequencing of pediatric rhabdomyosarcoma: report from the Children’s Oncology Group, the Children’s Cancer and Leukaemia Group, The Institute of Cancer Research UK, and the National Cancer Institute.

John Frederick Shern

10515

The addition of cycles of irinotecan/temozolomide (i/T) to cycles of vincristine, doxorubicin, cyclophosphamide (VDC) and cycles of ifosfamide, etoposide (IE) for the treatment of Ewing sarcoma (ES).

Paul A. Meyers

10533

The challenge of pediatric oncology: New business models to accelerate innovation.

Sonya Das

10528

The influence of surgical excision on survival in high-risk neuroblastoma revisited after introduction of ch14.18/CHO immunotherapy in the HR-NBL1/SIOPEN trial.

Keith Holmes

10521

The randomised induction for high-risk neuroblastoma comparing COJEC and N5-MSKCC regimens: Early results from the HR-NBL1.5/SIOPEN trial.

Alberto Garaventa

10507

Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)–associated plexiform neurofibroma: A phase I/IIa study.

Geoffrey Brian McCowage

10504

Various checkpoint proteins, and tumor infiltrating lymphocytes in common pediatric solid tumors: Possibilities for novel immunotherapy.

Kazuhiro Mochizuki

10544

Visceral primary non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) in patients < 30 years of age: Findings of Children’s Oncology Group (COG) study ARST0332.

Meena Kadapakkam

10545

Who are the high risk medulloblastoma subgroups in Jordan?

Nisreen Yousef Amayiri

e22506